Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Vomiting 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Nausea 1Carcinoma in Situ 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Granisetron × 1 year × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT00343460 2026-03-02

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Heron Therapeutics

Phase 3 Completed
1,428 enrolled 21 charts

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡